ALCLS Fundamental Analysis - CELLECTIS

Fundamental Rating

ALCLS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 83 industry peers in the Biotechnology industry. Both the profitability and financial health of ALCLS have multiple concerns. ALCLS is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

ALCLS had negative earnings in the past year.

In the past year ALCLS has reported a negative cash flow from operations.

In the past 5 years ALCLS always reported negative net income.

In the past 5 years ALCLS reported 4 times negative operating cash flow.

1.2 Ratios

ALCLS has a Return On Assets of -28.30%. This is comparable to the rest of the industry: ALCLS outperforms 46.99% of its industry peers.

Looking at the Return On Equity, with a value of -103.16%, ALCLS is in line with its industry, outperforming 45.78% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-28.3%
ROE	-103.16%
ROIC	N/A

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ALCLS has a worse Gross Margin (3.66%) than 62.65% of its industry peers.

The Profit Margin and Operating Margin are not available for ALCLS so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	3.66%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ALCLS does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ALCLS has been increased compared to 1 year ago.

The number of shares outstanding for ALCLS has been increased compared to 5 years ago.

ALCLS has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -0.27, we must say that ALCLS is in the distress zone and has some risk of bankruptcy.

ALCLS has a Altman-Z score of -0.27. This is comparable to the rest of the industry: ALCLS outperforms 45.78% of its industry peers.

ALCLS has a Debt/Equity ratio of 0.91. This is a neutral value indicating ALCLS is somewhat dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.91, ALCLS is in line with its industry, outperforming 43.37% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.91
Debt/FCF	N/A
Altman-Z	-0.27

ROIC/WACCN/A

WACC6.67%

2.3 Liquidity

ALCLS has a Current Ratio of 1.38. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

ALCLS's Current ratio of 1.38 is on the low side compared to the rest of the industry. ALCLS is outperformed by 65.06% of its industry peers.

ALCLS has a Quick Ratio of 1.38. This is a normal value and indicates that ALCLS is financially healthy and should not expect problems in meeting its short term obligations.

The Quick ratio of ALCLS (1.38) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	1.38
Quick Ratio	1.38

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ALCLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.80%, which is quite impressive.

The Revenue has grown by 154.92% in the past year. This is a very strong growth!

The Revenue has been growing by 16.44% on average over the past years. This is quite good.

EPS 1Y (TTM)70.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%104.35%

Revenue 1Y (TTM)154.92%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%105.89%

3.2 Future

Based on estimates for the next years, ALCLS will show a very negative growth in Earnings Per Share. The EPS will decrease by -75.92% on average per year.

ALCLS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 25.15% yearly.

EPS Next Y-167.21%

EPS Next 2Y-83.7%

EPS Next 3Y-75.92%

EPS Next 5YN/A

Revenue Next Year45.52%

Revenue Next 2Y17.95%

Revenue Next 3Y12.51%

Revenue Next 5Y25.15%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

ALCLS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year ALCLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ALCLS's earnings are expected to decrease with -75.92% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-83.7%

EPS Next 3Y-75.92%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ALCLS!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CELLECTIS

EPA:ALCLS (12/5/2025, 7:00:00 PM)

4.12

-0.12 (-2.83%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-07 2025-11-07/amc

Earnings (Next)03-11 2026-03-11/amc

Inst Owners15.56%

Inst Owner ChangeN/A

Ins Owners2.82%

Ins Owner ChangeN/A

Market Cap413.34M

Revenue(TTM)112.63M

Net Income(TTM)-100.18M

Analysts84.62

Price Target6.63 (60.92%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)14.93%

Min EPS beat(2)4.37%

Max EPS beat(2)25.48%

EPS beat(4)4

Avg EPS beat(4)48.46%

Min EPS beat(4)4.37%

Max EPS beat(4)145.69%

EPS beat(8)7

Avg EPS beat(8)30.86%

EPS beat(12)9

Avg EPS beat(12)22.27%

EPS beat(16)12

Avg EPS beat(16)21.54%

Revenue beat(2)1

Avg Revenue beat(2)21.17%

Min Revenue beat(2)-20.05%

Max Revenue beat(2)62.39%

Revenue beat(4)3

Avg Revenue beat(4)64.94%

Min Revenue beat(4)-20.05%

Max Revenue beat(4)161.56%

Revenue beat(8)5

Avg Revenue beat(8)33.5%

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)0%

EPS NY rev (1m)14.88%

EPS NY rev (3m)14.88%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)0%

Revenue NY rev (1m)50.74%

Revenue NY rev (3m)50.74%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	5.15
P/FCF	N/A
P/OCF	N/A
P/B	4.96
P/tB	5.02
EV/EBITDA	N/A

EPS(TTM)-0.28

EYN/A

EPS(NY)-1.01

Fwd EYN/A

FCF(TTM)-0.31

FCFYN/A

OCF(TTM)-0.29

OCFYN/A

SpS0.8

BVpS0.83

TBVpS0.82

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-28.3%
ROE	-103.16%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	3.66%
FCFM	N/A

ROA(3y)-26.82%

ROA(5y)-25.52%

ROE(3y)-79.12%

ROE(5y)-63.67%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.26

Health

		Industry Rank	Sector Rank
Debt/Equity	0.91
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	16.04%
Cap/Sales	3.51%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.38
Quick Ratio	1.38
Altman-Z	-0.27

F-Score3

WACC6.67%

ROIC/WACCN/A

Cap/Depr(3y)12.8%

Cap/Depr(5y)139.39%

Cap/Sales(3y)9.66%

Cap/Sales(5y)33.81%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)70.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%104.35%

EPS Next Y-167.21%

EPS Next 2Y-83.7%

EPS Next 3Y-75.92%

EPS Next 5YN/A

Revenue 1Y (TTM)154.92%

Revenue growth 3Y8.44%

Revenue growth 5Y16.44%

Sales Q2Q%105.89%

Revenue Next Year45.52%

Revenue Next 2Y17.95%

Revenue Next 3Y12.51%

Revenue Next 5Y25.15%

EBIT growth 1Y46.16%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-5.42%

EBIT Next 3Y-33.24%

EBIT Next 5Y-29.24%

FCF growth 1Y51.3%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y55.32%

OCF growth 3YN/A

OCF growth 5YN/A

CELLECTIS / ALCLS.PA FAQ

Can you provide the ChartMill fundamental rating for CELLECTIS?

ChartMill assigns a fundamental rating of 2 / 10 to ALCLS.PA.

Can you provide the valuation status for CELLECTIS?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTIS (ALCLS.PA). This can be considered as Overvalued.

What is the profitability of ALCLS stock?

CELLECTIS (ALCLS.PA) has a profitability rating of 1 / 10.

CELLECTIS (ALCLS.PA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

CELLECTIS / ALCLS.PA FAQ

Can you provide the ChartMill fundamental rating for CELLECTIS?

Can you provide the valuation status for CELLECTIS?

What is the profitability of ALCLS stock?